effect overlay
activetrials

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of NBI-921352 as Adjunctive Therapy in Adult Subjects with Focal Onset Seizures (FOS)
 

HREC: 2021.277
Principal Investigator: Dr John-Paul Nicolo
Coordinator contact: Elle Hurley
Funding: Commercial

Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects with Focal Onset Seizures (FOS)
 

HREC: 2022.141
Principal Investigator: Dr John-Paul Nicolo
Coordinator contact: Elle Hurley
Funding: Commercial
Epilepsy

A Prospective Study To Assess The Safety Of A Sub-Scalp Monitoring Device For The Recording Of Brain Electrical Activity Associated With The Occurrence Of Epileptic Seizures
 

HREC: 2022.246
Principal Investigator: Dr John-Paul Nicolo
Coordinator contact: Sean Hosking
Funding: Non-Commercial

A Phase 2, Multicenter, Open Label Safety and Tolerability Study of SPN-817 in Adult Patients with Treatment Resistant Epilepsy
 

HREC: 2022.261
Principal Investigator: Dr John-Paul Nicolo
Coordinator contact: Sean Hosking
Funding: Commercial

A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy
 

HREC: 2022.267
Principal Investigator: Dr John-Paul Nicolo
Coordinator contact: Elle Hurley
Funding: Commercial